Introduction
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cascade of cancer cell antigen release, antigen presentation by dendritic cells (DCs), activation of T lymphocytes, and migration of T cells into the tumor bed present errors in each step of the cancer immunity cycle. Therefore, therapeutic approaches to regaining anticancer immunity vary. These approaches include therapy with interleukins (ILs), interferons (IFNs), and antibodies against components of immune cells and the use of specific activating vaccines.
Activation or repression of functions of T cells is tightly controlled by specific immune checkpoint molecules, including cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1) and its ligand PD-L1, T-cell membrane protein 3 (TIM3), lymphocyte activation gene 3 (LAG3), and B-and T-lymphocyte attenuator (BTLA) [2] [3] [4] . In healthy individuals, autoimmune processes are blocked by sustaining and promoting the immune system's selftolerance [5] . Within a tumor's microenvironment, however, aberrant expression of specific immune molecules induces excessive immune tolerance and enables immune escape of tumor cells [2] . Therefore, immune checkpoint therapy is a promising strategy for combating cancer that differs from conventional cancer therapy in two major ways. First, by modulating T-cell-regulating molecules, immune checkpoint therapy kills tumor cells indirectly. Second, the aim of immune checkpoint therapy is to regulate immune responses in the tumor microenvironment by removing inhibitory factors rather than to activate the patient's immune system [6] .
In this review, we describe immune checkpoint inhibitors currently used for cancer therapy in clinical practice and their respective molecular targets. Next, we outline the role of microRNAs (miRNAs) in regulating immune response in the tumor microenvironment, emphasizing the roles of miRNAs as modulators of immune checkpoint molecules and their potential as cancer therapeutic targets and agents.
Immune checkpoint molecules

CTLA-4
Cytotoxic T-lymphocyte-associated antigen 4 is found on the surface of T cells and impedes early stages of T-cell activation by counteracting the prostimulatory effects of CD28 [7] . CTLA-4 and CD28 share the same ligands-CD80 and CD86-on the surface of antigenpresenting cells (APCs). CTLA-4 has greater affinity for these two ligands than CD28 has [8] . Detailed mechanisms of CTLA-4 blockage of T-cell activation are under investigation. After binding to CD80 and CD86, CTLA-4 activates the protein phosphatases PP2A and SHP2, which in turn counteract CD28-and T-cell-receptor-induced kinase activity [7] . Moreover, CTLA-4 actively removes CD80 and CD86 from the surface of APCs and dissolves their connection with CD28 [9] .
PD-1
The transmembrane glycoprotein PD-1 consists of an intracellular portion with two phosphorylation sites, a transmembrane region, and an extracellular immunoglobulin V domain [10] . PD-1 is mainly expressed on the surface of T cells and mitigates immune response by inducing apoptosis of antigenspecific T cells while reducing that of regulatory T cells [11] . High levels of PD-1 and its ligand PD-L1 expression are associated with poor prognosis for several cancers, as overactivation of the PD-1/PD-L1 pathway results in suppression of anticancer immune response [12] . Unlike conventional immunotherapy (e.g., T-cell modulation, vaccination), which is aimed at producing a systemic immune response, PD-1 pathway blockage induces immune processes directly in the tumor microenvironment. Therefore, blockage of the PD-1 pathway constitutes a promising approach to modulation of anticancer immune responses, especially in patients with solid tumors [13] .
PD-L1
PD-L1 and its fellow PD-1 ligand PD-L2 are members of the B7 family of transmembrane proteins, both of which interact with PD-1. Although PD-L2 is mainly found on the surface of APCs, PD-L1 is expressed by several immune system and cancer cells [14] . Structurally, PD-L1 contains the extracellular portion of the molecule composed of immunoglobulin V and C domains and a transmembrane region [4] . PD-L1 inhibits proliferation of conventional T cells by binding to PD-1, which is highly expressed on the surface of such T cells located in the tumor bed, impairing anticancer immunity. Concurrent loss of PD-1 expression on regulatory T cells enhances their activity, leading to additional inhibition of the activity of conventional T cells [15] .
LAG3
The only known ligands for LAG3 are major histocompatibility complex class II molecules, which are expressed by tumor-infiltrating macrophages and DCs [16] . Like with other immune checkpoint molecules, such as PD-1, LAG3 expression is upregulated in both regulatory and anergic T cells. Furthermore, it enhances the function of regulatory T cells and inhibits that of CD8+ effector T cells, promoting self-tolerance and immune escape of cancer cells [17] .
Blockage of LAG3 activity reverses the anergic state of T cells [18] , and simultaneous knockout of both LAG3 and PD-1 is even more effective in doing this than individual suppression of either molecule. However, concurrent knockout of PD-1 and LAG3 not only leads to T-cell-mediated antitumor immune response but also promotes the development of autoimmune processes [18] . This is one of the major problems with immunotherapy: tumor control via efficient modulation of the immune system may put patients at risk for fatal autoimmune diseases.
B7-H3 and B7-H4
B7-H3 and B7-H4 have more variable effects on the immune system than do most other members of the B7 family of inhibitory ligands, including CTLA-4 and CD28 [19] . In healthy tissue, expression of both B7-H3 and B7-H4 seems to be strictly regulated at the posttranscriptional level, as their respective mRNAs are frequently expressed, whereas their protein expression levels are rather low [20] . Although receptors for B7-H3 and B7-H4 have yet to be identified, these two ligands seem to exert immune-inhibitory functions [19] . B7-H3 is generally expressed in several types of tumors, and elevated B7-H3 expression in renal cell carcinoma (RCC) and prostate cancer cases is associated with poor clinical outcome [21] . Overexpression of B7-H4 is also common in ovarian and endometrial carcinoma, breast cancer, RCC, and prostate cancer cells. As with B7-H3, high levels of B7-H4 expression correlate with poor prognosis for cancer [19] . These inhibitory ligands are potential targets for immune checkpoint therapy, although the detailed mechanisms of how they modulate immune response are still under investigation.
TIM3
T-cell membrane protein 3 is expressed by different types of immune cells, including DCs, natural killer cells, T cells, and macrophages [22] . Known ligands of this immune checkpoint molecule include galectin-9 and high mobility group box 1 [23] . TIM3 is overexpressed in patients with various malignancies, including melanoma and liver and lung cancer [24] . It inhibits T-helper 1 cell response and enhances antitumor immunity. Simultaneous blockage of the functions of TIM3 and PD-1, which are frequently coexpressed on the surface of tumor-specific CD8+ cells, enhances antitumor immune response. As with PD-1 and LAG3, concurrent targeting of TIM3 and PD-1 is more effective at increasing antitumor immunity than is individual targeting of either molecule [25] .
BTLA B-and T-lymphocyte attenuator resembles PD-1 and CTLA-4 both structurally and functionally. It is predominantly expressed by activated T-helper cells. Following exposure to antigens, BTLA mitigates IL-2 production and seems to impair activation of T cells [26] . Herpesvirus entry mediator, which is frequently expressed on the surface of melanoma cells, is an important ligand for BTLA. In a tumor microenvironment containing herpesvirus entry mediator-positive tumor and tumor-associated endothelial cells, the function of BTLA-positive T cells is repressed [27] . Interestingly, knockout of BTLA causes the same susceptibility to autoimmune diseases as that observed in PD-1-knockout models, whereas spontaneous lymphoproliferative diseases develop in patients with CTLA-4 deficiency [26] . These observations indicate that BTLA and PD-1 may regulate T-cell activation at later stages than does CTLA-4.
Adenosine A2a receptor
Adenosine is the ligand of the adenosine A2a receptor (A2aR). By inducing expression of FOXP3 in CD4+ T cells, A2aR promotes their conversion into regulatory T cells and thus provokes immune tolerance [28] . The usually high cell turnover within a tumor results in elevated levels of adenosine, which is released by dying cells. Consequently, the adenosine-A2aR interaction seems to promote a self-sustaining mechanism by which tumors continuously proliferate and dedifferentiate while being attacked with decreasing intensity by the immune system [2] . Therefore, blockage of A2aR constitutes a potential immunotherapeutic approach for cancer. However, investigators have tested inhibition of A2aR function using either adenosine analogs or receptor-blocking antibodies only in patients with Parkinson disease; clinical trials with cancer patients are pending [2] .
Immune checkpoint inhibitors
In the late 1990s, researchers studied the fully human antibody ipilimumab, one of the first developed immune checkpoint inhibitors, in clinical trials based on the groundbreaking work of Dr. James Allison (now at The University of Texas MD Anderson Cancer Center) on CTLA-4 [29] [30] [31] . As a CTLA-4 inhibitor in particular, treatment with ipilimumab causes regression of various tumor types, especially melanoma [6] . In advanced melanoma cases, response rates were encouraging, with long-term overall survival rates ranging from 20% to 26% after treatment with ipilimumab compared with a 'historical' overall survival rate of only 10% [32] . Very recently, ipilimumab-based therapy has successfully expanded from that for incurable metastatic melanoma to adjuvant therapy in highrisk locally advanced melanoma patients [33] . Likewise, studies demonstrated promising results using anti-PD-1 antibodies, which proved beneficial in cases of melanoma, advanced RCC, nonsmall cell lung cancer (NSCLC), head and neck cancer, and bladder cancer, inducing both tumor regression and disease stabilization [34] . The most promising results were those for metastatic melanoma, with a 1-year survival rate of 72.9% after treatment with the PD-1 inhibitor nivolumab compared with 42.1% after chemotherapy [35] . Treatment with pembrolizumab, another PD-1 inhibitor, led to similar response rates. Moreover, 26% of metastatic melanoma patients with progressive disease after receiving ipilimumab-based therapy had responses to pembrolizumab-based treatment [36] . Because of these promising results, the U.S. Food and Drug Administration approved ipilimumab in 2011 and pembrolizumab and nivolumab 3 years later for treatment of metastatic melanoma. These drugs are currently the standard of care for this cancer in the first-line therapeutic setting [6] . Very recently, in a groundbreaking study, the PD-1 inhibitor pembrolizumab proved to be more efficient than classical cytotoxic chemotherapy in the first-line setting in NSCLC patients with PD-L1 expression in more than 50% of tumor cells [37] .
Several new approaches to blocking immune checkpoints are currently being investigated, of which combinations of different immune checkpoint inhibitors are among the most promising. For instance, the combination of ipilimumab and nivolumab in treatment of metastatic melanoma improved the response rate and major clinical endpoints in melanoma patients [38] . Another new approach is combining immune checkpoint inhibitors with molecules that block cancer signaling pathways, such as the mitogen-activated protein kinase and vascular endothelial growth factor pathways, or with classical cytotoxic drugs [39] .
Owing to mutations of the serine threonine kinase BRAF, the mitogen-activated protein kinase pathway is constitutively active and promotes tumor progression in nearly half of melanoma patients [40] . Moreover, activation of this pathway seems to promote immune escape by reducing the expression of melanoma-specific antigens in tumor cells [41] . Hence, blockage of mitogen-activated protein kinase signaling by BRAF inhibitors not only reduces tumor cell proliferation and survival but also re-exposes tumor cells to immune responses [42] . Based on these observations, several clinical trials evaluating the effect of cancer treatment with BRAF inhibitors in combination with immune checkpoint inhibitors (e.g., PD-1, CTLA-4, PD-L1) are ongoing or being planned [43] .
However, a problem of treatment with immune checkpoint inhibitors is the development of resistance, which may be present from the beginning of therapy or develop during it. Recent evidence suggests that primary failure of treatment with PD-1 inhibitors in metastatic melanoma patients is caused by innate anti-PD-1 resistance in up to 70% of cases [44] . This innate resistance seems to be strongly associated with epithelial-mesenchymal transition (EMT) and consecutive changes in the tumor's microenvironment [44] . Moreover, expression of macrophage chemotactic genes (e.g., CCL-2, -7, -8, -13), mesenchymal genes (TWIST2, AXL, LOXL2, and WNT5A), and immunosuppressive genes (VEGFA, IL10, and VEGFC) is considerably upregulated in tumors refractory to treatment with PD-1 inhibitors [44] . On the other hand, resistance to treatment with immune checkpoint inhibitors may be related to inactivation of IFN-cassociated pathways. For example, during treatment of melanoma with PD-1 inhibitors, inactivation of the IFN receptor-associated Janus kinases 1 and 2 results in disturbed response to experimental treatment with IFN-c [45] . Consequently, antigen presentation induced by IFN-c is impaired, as is its antiproliferative effects on tumor cells, resulting in acquired anti-PD-1 resistance [46] . Moreover, cumulative alterations of IFN-c pathway genes are likely to cause primary anti-CTLA-4 resistance in cancer cases. Amplification of IFN-c-inhibitory genes (SOCS1 and PIAS4) and concurrent copy-number loss of key IFN-c pathway genes (IRF1, Janus kinases 1 and 2, IFIT1, and IFNGR1/2) are observed in patients with melanoma unresponsive to treatment with anti-CTLA-4 agents [47] .
miRNAs
In 1993, Lee et al. [48] and Wightman et al. [49] discovered the first miRNA, lin-4, and its target, lin-14. Calin et al. [50] were the first to show the link between these tiny RNA molecules and cancer development. As noncoding RNA transcripts, miRNAs are composed of 18-24 nucleotides and regulate gene expression by binding to the 3 0 untranslated region (UTR) of a specific mRNA [51] . Although miRNAs resemble smallinterfering RNAs in their structure and function, they are of different biogenetic origin [52] . Specifically, although small-interfering RNAs originate from long double-stranded RNA precursors, miRNAs originate from transcripts forming stem-loop structures. Via complex mechanisms in both the nucleus and cytoplasm, primary miRNAs are converted into precursor miRNAs and finally processed by the cytoplasmic RNase III endonuclease complex Dicer into miRNAs. Merging with the RNA-induced silencing complex enables miRNAs to regulate gene expression via RNA interference [53] . This mRNA-miRNA interaction leads to either translational arrest or degradation of the respective mRNAs [54] .
MicroRNA is aberrantly expressed in any type of malignancy studied to date, as they actively regulate both tumor suppressor genes and oncogenes [55] . They are ideal diagnostic biomarkers owing to their greater stability in body fluids and biopsy specimens than that of long noncoding RNAs and mRNAs [56, 57] .
Because miRNA expression patterns are quite tissuespecific, quantification of them in patients with cancer of unknown primary may speed up the diagnosis of specific types of cancer [56] . Moreover, specific miRNA signatures can be both predictive of and prognostic for different types of cancer [58] . By regulating the development and differentiation of immune progenitor cells into mature immune cells, miRNAs potentially affect the anticancer immune response [59] .
miRNAs and immune checkpoints
MicroRNAs are involved in a variety of immune checkpoint-related processes (Figs 1 and 2) . The following sections provide insight into the diverse roles of miRNAs as regulators of immune checkpoint molecules and related pathways. [60]. In ovarian carcinoma cells, however, only miR-424 (322) seems to inhibit their expression by directly binding to mRNA. Low miR-424 (322) expression levels are not only associated with high CD80 and PD-L1 expression levels but also highly correlated with chemoresistance [60] . Overexpression of miR-424 (322) leads to reduced CD80 protein expression in DCs. Additionally, miR-424 (322) blocks the CD80/CTLA-4 immune checkpoint pathway by reducing CD80 protein levels in DCs and potentially enhances stimulation of T cells [9, 60] .
Another miRNA with tumor-suppressive functions is miR-28. Its expression is downregulated by about 30% in exhausted PD-1+ T cells extracted from melanomas [61] . It inhibits the expression of the immune checkpoint molecules TIM3, BTLA, and PD-1 in T cells by binding to their respective 3 0 UTRs. Expression of all of these immune checkpoint molecules is indicative of an exhausted T-cell phenotype. Details on the interaction of miR-28 with exhausted T cells are described below.
Owing to its tumor-suppressive functions, miR-138 expression is likewise downregulated in various malignancies. It induces apoptosis of cancer cells, prevents EMT by reducing vimentin expression, and impairs metastatic spread by directly targeting the transcription factors SOX4 and hypoxia-inducible factor-1a [62, 63] . Furthermore, miR-138 inhibits expression of the immune checkpoint molecules PD-1 and CTLA-4 on the surface of both effector and regulatory T cells by binding to their 3 0 UTRs [64] . miR-138 mimics may have a role in cancer immunotherapy, as they can adapt a tumor's microenvironment to make it susceptible to anticancer immune response.
PD-L1
The miR-34 family comprises the miRNAs miR-34a, -34b, and -34c. Owing to its tumor-suppressive functions, expression of miR-34a is frequently downregulated in solid malignancies [65] . It directly targets the 3 0 UTR of PD-L1 and inhibits expression of this immune checkpoint molecule. In acute myeloid leukemia and NSCLC cells, low levels of miR-34a expression correlate with PD-L1 overexpression on the cell surface [65, 66] . The tumor suppressor p53 induces upregulation of miR-34a expression [67] . Consequently, miR-34a suppresses expression of PD-L1 [66] . In NSCLC patients, the combination of low p53 and high PD-L1 expression and that of low p53 and miR34a expression is associated with poor clinical outcome [66] . Moreover, miR-34a affects the phenotype of exhausted CD8+/PD-1+ T cells by impairing PD-1/ PD-L1 interaction and inducing secretion of IFN-c and tumor necrosis factor-a. The safety of MRX34, a liposomal formulation containing miR-34a mimics, in cancer patients was under investigation in a phase 1 clinical trial [68] . Unfortunately, owing to major immune-related adverse events, the trial was recently suspended, proving that very detailed toxicity studies and combinatorial strategies using reduced doses of miRNA mimics/anti-miRNA agents are desirable.
As with miR-34a, miR-138-5p, the 5 0 -arm transcript of precursor miRNA-138, has tumor-suppressive functions. Expression of this miRNA is frequently downregulated in colorectal cancer (CRC) cells [69] , and low miR-138-5p expression correlates with advanced disease, lymph node metastasis, and poor clinical outcome. These correlations can be explained by the effects of miR-138-5p on tumor cells. First, miR-138-5p expression impedes proliferation of CRC cells. Second, it blocks their transition from G1 to S phase of the cell cycle [69] . Third, miR-138-5p directly inhibits PD-L1 expression by binding to its 3 0 UTR. Of note, restoration of PD-L1 expression reverses blockage of both cellular proliferation and cell cycle progression, indicating that miR-138-5p regulates both processes by reducing PD-L1 expression [69] . Overexpression of PD-L1 in combination with low expression of miR-138-5p predicts poor clinical outcome of CRC. In CRC patients with this correlated expression, administration of miR-138-5p mimics that cause blockage of the PD-L1 pathway may be an effective therapeutic strategy.
In contrast with miR-138-5p, miR-20b, -21, and130b are frequently overexpressed in CRC cells [70] . They promote tumorigenesis by targeting the 3 0 UTR of PTEN with consequent protein downregulation, an important suppressor of the phosphoinositide 3-kinase/ Akt/mammalian target of rapamycin pathway [71] . Additionally, low PTEN expression is associated with PD-L1 overexpression in tumors. Therefore, miR-20b, -21, and -130b seem to indirectly mitigate T-cell activation in the tumor microenvironment by inhibiting expression of PTEN [70] .
Because a single miRNA can target multiple mRNAs, several pathways may be dysregulated in cancers with aberrant miRNA expression. For example, miR-200 is involved in the regulation of EMT and PD-L1 expression in tumor cells. EMT is an important driver of metastasis, as loosening cell-cell contacts during this transition facilitate cellular motility, invasion, and dissemination [72] . P53 efficiently suppresses EMT by inhibiting expression of the EMT-promoting transcription factors zinc-finger E-box-binding homeobox 1 and 2. However, many tumors have inactivating p53 mutations, resulting in enhanced tumor progression and metastatic spread [73] . In cancer cells, miR-200 impedes these processes by directly targeting zinc-finger E-box-binding homeobox 1 following transactivation by p53 [74] . Conversely, expression of zincfinger E-box-binding homeobox 1 represses transcription of miR-200 and induces EMT. Therefore, the miR-200/zinc-finger E-box-binding homeobox 1 double-negative feedback loop is an important regulator of EMT [75] that explains why loss of miR-200 expression in CRC and hepatocellular carcinoma cells, for example, is associated with poor clinical outcome [76, 77] . Another miRNA whose aberrant expression influences immune checkpoint molecules and other tumorrelated pathways is miR-197. Its downregulation leads to dysregulation of various signaling pathways, resulting in enhanced tumor progression and multidrug resistance [78] . In NSCLC cells, miR-197 directly inhibits expression of the cyclin-dependent kinase CKS1B, which in turn interacts with the transcription factor signal transducer and activator of transcription 3 [79] . Furthermore, low miR-197 expression levels promote CKS1B-induced phosphorylation of signal transducer and activator of transcription 3. Activated signal transducer and activator of transcription 3 (STAT3) not only upregulates expression of the oncogenes Bcl-2, cyclin D1, Survivin, and c-Myc but also drives expression of PD-L1 in tumor cells [79, 80] . Overexpression of PD-L1 induced by the miR-197/CKS1B/signal transducer and activator of transcription 3 cascade seems to promote resistance of NSCLC to treatment with cisplatin and paclitaxel [79] . However, the exact mechanisms of how PD-L1 promotes chemoresistance besides its immunosuppressive function have yet to be identified. Nevertheless, low miR-197 expression levels are correlated with high PD-L1 expression levels, promote chemoresistance, and are associated with decreased overall survival of NSCLC patients [79] . Because of this inverse correlation, PD-L1-positive NSCLC patients may benefit from therapy with miR-197 mimics.
Recent evidence suggests that viral miRNAs, especially those belonging to the herpesvirus family, expressed for long durations after infection influence the pathogenesis of and prognosis for several malignancies by modulating the patient's immune system [81] . How tumors exactly express viral miRNAs is still under investigation. However, three models could explain this process: (a) circulating viral miRNAs produced at remote sites can be absorbed by tumors, (b) viral miRNA is autologously produced by tumor cells, and (c) viral miRNA is autologously produced by non-neoplastic tumor-infiltrating cells (e.g., B lymphocytes) [81] . The Epstein-Barr virus (EBV) miR-BART cluster comprises the miRNAs miR-BART-2, -4, -5, -18, and -22. Cells in various solid malignancies can express this cluster, including those in CRCs, head and neck squamous cell carcinomas, and gastric adenocarcinomas [82] . EBV miR-BART cluster-positive solid malignancies have marked upregulation of PD-L1 and PD-1 expression [82] . Moreover, expression of the EBV miR-BART cluster is associated with amplified secretion of the suppressive immune modulators IFNc, transforming growth factor-b1, and IL-10, indicating that these five viral miRNAs actively suppress immune responses within the tumor microenvironment. Patients with tumors expressing this miRNA cluster have rather poor prognoses [82] . Consequently, EBV miR-BART cluster-positive cancer patients may benefit from the use of therapeutics blocking virusinduced cytokine production as well as PD-1 and PD-L1 expression [82] .
In patients with chronic inflammation of the biliary tract, enhanced secretion of proinflammatory cytokines, including tumor necrosis factor-a and IFN-c, can occur [83] . Besides enhancing cellular turnover, cholestasis, and fibrosis, IFN-c promotes expression of PD-L1 while suppressing the expression of miR-513 together with 75 other miRNAs [84] . miR-513 prohibits PD-L1 expression by binding to its 3 0 UTR. Additionally, miR-513 seems to impair IFN-cinduced PD-L1 protein expression in cholangiocytes despite their having unaltered PD-L1 mRNA expression [84] . These observations indicate that PD-L1 expression in biliary tract cells during chronic inflammation is triggered by both elevated IFN-c expression and suppressed inhibitory functions usually exerted by miR-513 [84] . Considering that chronic inflammation is important for malignant transformation of cholangiocytes, targeting the IFN-c/miR-513/ PD-L1 axis in patients with cholangiopathies may save them from cholangiocarcinoma later on. Researchers have observed the tumorigenic potential of miR-513/PD-L1 interaction in retinoblastoma patients as well [85] . During treatment with etoposide, PD-L1 expression levels increase, whereas miR-513-5p expression levels decrease in retinoblastoma cells. Supporting the correlation of expression of PD-L1 and miR-513-5p, PD-L1 expression levels gradually decline with the addition of miR-513-5p mimics to retinoblastoma cells [85] .
First identified as a crucial component of the miRNA gene network in patients with alcoholic liver disease, miR-570 expression is frequently downregulated in hepatocellular carcinoma cells [86, 87] . Because PD-L1 is a direct target of miR-570, it is overexpressed in hepatocellular carcinoma cells with low miR-570 expression. Moreover, PD-L1 expression positively correlates with progression and invasion of hepatocellular carcinoma cells. On the other hand, these processes are reversed by miR-570 via suppression of PD-L1 function [86] . In gastric adenocarcinoma cells, the single-nucleotide polymorphism rs4143815 in the 3 0 UTR of PD-L1 mRNA impairs the binding with miR-570 [88] . Consequently, somatic mutations from the G to the C allele at rs4143815 are associated with increased risk of gastric adenocarcinoma owing to chronically elevated PD-L1 expression [89] . In this subset of patients with gastric adenocarcinoma, miR-570 mimics may have roles as immune checkpoint inhibitors, and rs4143815 can be further developed as a biomarker of response of this cancer to anti-PD-L1 therapy.
PD-1
As described in the section above on PD-L1, solid tumors positive for the EBV miR-BART cluster, such as head and neck squamous cell carcinoma, also express PD-1 at high levels [82] . Although how expression of EBV miRNAs leads to overexpression of the respective immune checkpoint molecules is uncertain, therapeutic suppression of the expression of these miRNAs may reverse silencing of anticancer immune response by blocking the PD-1/PD-L1 pathway.
On the other hand, miR-138 expression is frequently downregulated in head and neck squamous cell carcinoma as well as anaplastic thyroid carcinoma and ovarian cancer cells [62, 63] . As described above, miR-138 impedes the expression of PD-1 and CTLA-4 by targeting their 3 0 UTRs [64] . In glioma cell lines, miR-138 transfection promotes anticancer immunity by suppressing the expression of immune checkpoint molecules and is associated with significant tumor shrinkage [64] .
Exhausted T cells usually express various immune checkpoint molecules, including BTLA, LAG3, TIM3, and PD-1, at high levels on their surfaces [90] . By reducing secretion of several cytokines, exhausted T cells further adapt a tumor's microenvironment in favor of malignant cells. In the exhausted state, T cells constantly lose their effector functions, ranging from decreased IL-2 production and impaired proliferative ability to reduced IFN-c and tumor necrosis factor secretion [91] . Interaction between PD-1+ T cells and PD-L1+ tumor cells seems to promote this process [92] .
Exhausted PD-1+ T cells in melanomas express 11 miRNAs differently from that in PD-1À T cells. Among them, miR-28 expression is downregulated by 30% in PD-1+ T cells [61] . This miRNA usually inhibits expression of TIM3, BTLA, and PD-1 by binding to their 3 0 UTRs [61] . Experimentally, miR-28 mimics can convert the exhaustive phenotype of exhausted PD-1+ cells, at least in part, by increasing secretion of IL-2 and tumor necrosis factor-a in T cells [61] . Moreover, miR-28 reduces cellular proliferation in B-cell lymphomas by silencing MAD2L1, a component of the cell cycle's spindle checkpoint [93] . Because of its involvement in T-cell regulation and tumor cell proliferation, miR-28 is a potential target for cancer therapy.
Using anti-miRNAs in combination with checkpoint inhibitors for cancer treatment
Expression of immune checkpoint molecules is regulated by miRNAs. Therefore, we envision two alternative strategies for modulation of this expression. The first strategy is the use of miRNA mimetics (Table 1) to restore the expression of downregulated miRNAs that target immune checkpoint mRNAs in both malignant cells and T lymphocytes in the tumor microenvironment. This will reduce the expression of checkpoint proteins and consequently reduce their downstream effects on malignant and immune cells similarly to the effects of treatment with the antibody-based drugs immune checkpoint inhibitors. For example, patients with early-stage NSCLC having high levels of expression of PD-L1 protein on the surface of malignant cells may benefit from PD-L1 blockage by treatment with miR-200 mimics. miRNA mimic molecules are double-stranded miRNAs delivered in nanoparticles that can be coated with antibodies against tumorspecific antigens, allowing for tumor-specific delivery of miRNAs of interest [90] .
Because an miRNA can target multiple checkpoint transcripts, targeting multiple types of cells in the same tumor will mimic the effect of treatment with multiple checkpoint inhibitors that act on different receptors. One example is the miR-138 mimetic, which can mimic the effects of anti-PD-1 and anti-CTLA-4 antibodies.
The second strategy is to use anti-miRNAs to block the expression of miRNAs that target immune checkpoint mRNAs in both compartments of a tumor: malignant cells and tumor microenvironmental cells (including tumor-associated macrophages and various types of immune cells). Most of the anti-miRNAs used for this purpose are the bicyclic RNA oligonucleotides locked nucleic acid (LNA) anti-miRNAs [94] . Another class of anti-miRNAs is composed of the antagomirs, anti-miRNA molecules characterized by cholesterol conjugation at the 3 0 terminus, and O-Me oligonucleotides with terminal phosphorothioate linkage at the 2 0 terminus to prevent degradation of antagomirs and increase their binding affinity for miRNAs that must be silenced [95] . LNA anti-miRNAs have an advantage over antagomirs in that they can be administered in single intraperitoneal injections, with dose-dependent silencing of the target miRNA. Investigators have also observed no acute or chronic toxic effects of treatment with LNA anti-miRNAs in animals [96] . An important advantage of using combination therapy with anti-miRNAs agents plus chemotherapy or targeted therapy agents such as small molecules or antibodies over use of them alone is the administration of reduced doses of anti-miRNAs and, potentially, immune checkpoint inhibitors, reducing the potential for adverse reactions. This is more important after the recent suspension of a clinical trial by Mirna Therapeutics, a clinical-stage biopharmaceutical company in Austin, TX, using miR-34 restitution with MRX34 in patients with metastatic solid tumors owing to multiple severe immune-related adverse events.
Conclusions
Substantial progress in basic cancer research, including detailed investigation of cancer metabolism, detection of novel cancer signaling pathways involving noncoding RNA transcripts, and the discovery of roles of the tumor microenvironment in development of malignancies, has revolutionized cancer treatment over the past few years. No longer the ideal goal of a 'magic bullet' for all malignancies, cancer treatment has moved toward targeted therapy and individualized treatment concepts. In this respect, immunemodulating treatment approaches, including IFN-and IL-based therapy, vaccines, and the use of immune checkpoint inhibitors, have proven beneficial. Researchers have achieved tremendous success with these approaches, especially the last one. In metastatic melanoma patients in particular, administration of the CTLA-4 inhibitor ipilimumab increased the overall survival rate from 10% to nearly 26%. Furthermore, treatment with the PD-1 inhibitor nivolumab proved beneficial in patients with advanced melanoma, RCC, or NSCLC, and the combination of ipilimumab and nivolumab has markedly improved clinical outcomes of cancer.
Nevertheless, potential disadvantages and pitfalls of immune checkpoint therapy must be taken into consideration. Not only do tumors continuously mutate and adapt to their environments, but also the patient's immune system perpetually changes and adjusts to the therapeutic blockade. Moreover, a reliable biomarker predicting tumor response to immune checkpoint inhibition has yet to be identified. Because small regulatory noncoding RNAs such as miRNAs [97] regulate the expression of immune checkpoint transcripts, secreted miRNAs in plasma can be tested as predictive biomarkers for response to therapy. Other longer noncoding RNAs [98, 99] also may be involved in the immune checkpoints functional modulation, and this is at present time a completely unexplored topic.
Although indications for the use of immune checkpoint inhibitors are constantly broadening, it is still more or less limited to certain tumor types and stages. However, treatment success cannot be guaranteed even in such cases because of a lack of predictive biomarkers. In this respect, miRNAs may be of major significance. Because defined miRNA expression patterns are associated with specific alterations in immunemodulating pathways, the pathway affected most can be identified by analyzing the miRNA profile of various immune cells. Consequently, decisions on whether to use specific immune checkpoint inhibitors should be made based on a tumor's miRNA signature rather than the underlying pathology or tumor stage.
Nevertheless, various factors potentially influence immune response in the cancer patient, ranging from the patient's genetic background to slight differences in immune-modulating pathways to the patient's microbiome. Likewise, the response of a tumor to treatment with immune checkpoint inhibitors is influenced by multiple parameters. That a tumor with high mutational loads responds well to immune-modulating therapy owing to elevated expression of neoantigens potentially inducing T-cell activation seems reasonable. However, RCCs respond to nivolumab-based immune therapy despite few genomic mutations in these tumors.
Therapeutic inhibition of immune checkpoints has brought cancer treatment one step closer to targeted, individualized therapy. Clinical trials with promising targeted therapeutic agents are currently planned or in progress or have been completed, with satisfactory results in many cases.
Basic scientific research conducted over the past 20 years has laid the groundwork for immunemodulating therapy, be it cytokine-or immune checkpoint inhibitor-based. Today, the steadily increasing diversity of diagnostic and therapeutic methods used in oncological research paves the way for even better understanding, prevention, and treatment of cancer.
